posaconazole

12/01/2011 - "Posaconazole prophylaxis has proven highly effective in preventing invasive fungal infections, despite relatively low serum concentrations. "
05/01/2014 - "Adequate penetration to the infection/colonization site is crucial to attain optimal efficacy of posaconazole against Aspergillus fumigatus diseases. "
11/01/2011 - "Posaconazole, a triazole antifungal agent with proven efficacy for prophylaxis and treatment of fungal infections, is often limited by poor absorption. "
01/01/2006 - "A large number of experimental animal models of invasive fungal infections has demonstrated the potent and broad-spectrum efficacy of posaconazole in vivo, both in normal and in immunocompromised animals. "
09/01/2012 - "The broad-spectrum triazole posaconazole showed promising results in preventing invasive fungal infections (IFIs) in high-risk patients. "

08/01/2015 - "An observational study was performed in 29 adult patients with acute myeloid leukemia who initially received posaconazole oral suspension 200 mg 3 times daily and required ≥1 dose adjustment because of steady-state posaconazole serum concentration <0.7 mcg/mL. Four dosing schemas were compared simultaneously. "
09/01/2015 - "Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia."
08/01/2015 - "Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia."
04/01/2014 - "Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia."
04/01/2012 - "Posaconazole is effective as primary antifungal prophylaxis of invasive fungal diseases in patients with acute myeloid leukemia. "

03/01/2013 - "In vivo, combination therapy was associated with improved survival in the fly model of mucormycosis (65% vs 57% posaconazole alone) and with significant reductions in cutaneous lesions and R. "
06/01/2009 - "To demonstrate that the 2-yr clinical follow-up of our patient strongly suggests that long-term therapy with posaconazole (POS) is safe and beneficial in treatment and prevention of relapses of, otherwise fatal, central nervous system mucormycosis. "
12/01/2012 - "This is the first report of the safe and effective use of posaconazole for the treatment of mucormycosis in a cirrhotic patient."
10/01/2015 - "Primary antifungal therapy with posaconazole can be considered in selected cases of cutaneous mucormycosis."
09/01/2015 - "In the posaconazole PAP group, two cases of breakthrough mucormycosis were noted among 13 proven/probable/possible IFI cases (15.4%). "

01/01/2014 - "Posaconazole is a triazole derivative which is effective in Aspergillosis prophylaxis and treatment. "
03/01/2015 - "We investigated the efficacy of posaconazole prophylaxis in preventing invasive aspergillosis due to azole-resistant Aspergillus fumigatus isolates. "
02/01/2010 - "The in vivo efficacy of posaconazole against 4 clinical Aspergillus fumigatus isolates with posaconazole MICs ranging from 0.03 to 16 mg/liter, as determined by CLSI method M38A, was assessed in a nonneutropenic murine model of disseminated aspergillosis. "
10/01/2004 - "We compared posaconazole with other antifungals for efficacy against murine CNS aspergillosis. "
10/01/2004 - "Efficacy of posaconazole in a murine model of central nervous system aspergillosis."

10/01/2006 - "On the basis of compassionate treatment data, posaconazole appears to be effective for treatment of zygomycosis. "
10/01/2010 - "Our findings showed that posaconazole could be useful in the treatment of zygomycosis. "
11/01/2008 - "Posaconazole as first line treatment for disseminated zygomycosis."
01/01/2007 - "It is not known whether posaconazole is effective as primary therapy for zygomycosis; the use of this agent for that purpose awaits clinical trials with the recently developed intravenous formulation of posaconazole."
01/01/2013 - "In patients with extensive zygomycosis, a triple-antifungal regimen, combined with therapeutic drug monitoring of posaconazole, may be helpful."